HEPATITIS B REACTIVATION RISK IN PATIENTS WITH RHEUMATOLOGIC DISEASES UNDER BIOLOGIC TREATMENT
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Carbone Editore
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction: Hepatitis B virus reactivation (HBVr) is a clinical entity that can occur due to the use of immunosuppressive medications and causes serious complications that can threaten survival. In this study, we aimed to investigate the effects of the biological agents used in rheumatology on HBVr in a large patient population. Materials and methods: Patients with rheumatologic diseases who were on biological treatment were analyzed according to hepatitis B virus (HBV) serology. Patients with resolved HBV and inactive chronic HBV were included in the study. Prophylaxis status, HBVr and hepatic flare were recorded. Results: 749 patients were screened by medical records. 106 (14.2%) patients were in the resolved HBV group and 15 (2%) patients were inactive HBV carrier. Prophylaxis was not administered to 74 (69.8 %) patients in the resolved HBV group and 4 (26.7%) patients in the inactive chronic HBV group. None of the patients demonstrated HBVr. Conclusion: We suggest that long-term prophylactic oral antiviral treatment can be avoided by the close follow-up of patients who were on tumour necrosis factor a (TNF a) or cytokine inhibitors due to low HBVr risk. On the other hand, patients receiving rituximab must be more carefully evaluated to prevent patients from not receiving antiviral prophylaxis.
Açıklama
Anahtar Kelimeler
cytokine inhibitors, hepatitis B reactivation, rheumatology, resolved HBV, rituximab, TNF a inhibitors
Kaynak
Acta Medica Mediterranea
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
37
Sayı
3
